Shah A

Texas Institute for Graduate Medical Education and Research , ,

9 papers

ArticleKetamine

Clinical Outcomes of Ketamine Therapy for Depression, Anxiety, and PTSD in Post-TBI Patients

Aldulaimy W, Shah A

ArticleKetamine

Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray.

Clemens K, Zhdanava M, Teeple A +6

ArticleKetamine

Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression.

Clemens K, Teeple A, Zhdanava M +6

ArticleKetamine

Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA.

Jha MK, Zhdanava M, Shah A +4

ArticleKetamine

Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States.

Harding L, Zhdanava M, Teeple A +4

ArticleKetamine

Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States.

Clemens K, Zhdanava M, Teeple A +5

ArticlePsilocybin

Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review.

Kim A, Halton B, Shah A +2

ArticleKetamine

Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray.

Harding L, Zhdanava M, Shah A +5

ArticleKetamine

Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.

Zhdanava M, Teeple A, Pilon D +3